Meet Aprille Espinueva, our Clinical Research Director of Global Metabolism. Aprille pursues her passion for clinical studies in #MASH (metabolic dysfunction-associated steatohepatitis), driving our exploration into the potential of #CortisolModulation forward. Curious about joining our team? Discover more career opportunities: https://lnkd.in/gG_8kxaG #WereHiring #ScienceCareers #Metabolics
Corcept Therapeutics
Biotechnology Research
Redwood City, California 35,192 followers
Pioneering the discovery and development of cortisol modulators.
About us
At the center of discovery and development of cortisol modulation. Our mission is to unlock the potential of cortisol and revolutionize the treatment of serious diseases. For the last 25 years, we’ve led the way in the research and development of selective glucocorticoid receptors (GR) antagonists, molecules that alter GR and regulate cortisol levels. In 2012, we received FDA approval of a groundbreaking cortisol receptor blocker and the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, global partnerships and collaborations form the bedrock of our robust development programs, including more than 500 GR antagonists for conditions spanning oncology, endocrine, and an array of metabolic disorders. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. We embrace possibility. We are Corcept.
- Website
-
http://www.corcept.com
External link for Corcept Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Redwood City, California
- Type
- Public Company
- Founded
- 1998
Locations
-
Primary
101 Redwood Shores Pkwy
Redwood City, California 94065, US
Employees at Corcept Therapeutics
Updates
-
For more than 12 years, we have been deeply involved with the #CushingsSyndrome patient community. Giving a voice to the patient experience is vital to ensuring their needs and values are considered at every stage of care. In this inspiring video, Deile shares her journey to diagnosis and treatment, and how it transformed her life. Thank you to Deile and the many patients whose voices go unheard, far too often. #PatientStorytelling #DeilesCushingsJourney
-
In honor of #NationalWellnessMonth, we're highlighting the extensive benefits we provide to support the health and wellbeing of our employees and their families. Our programs are designed to promote both professional success and personal fulfillment. To learn more about benefits and open roles, visit https://lnkd.in/gFWg_-yh #Hiring #OpenRoles #BiotechCareers
-
-
We recently had the opportunity to sit down with Kelly Close and the summer associates at Close Concerns to discuss #hypercortisolism and the potential impact in difficult to control #Type2Diabetes. Thank you to Kelly and the medical students for taking the time for this important issue. You are an invaluable educational resource to the diabetes community! (Subscription is required to read the full article.) https://lnkd.in/dbjGD_C #T2D #DiabetesEducation #endocrinology #DiabetesCare
-
Dr. Lewis Blevins' book emphasizes the importance of broadening awareness of Cushing’s Syndrome and its diagnosis. In his latest work, the PITUITARY WORLD NEWS co-founder shares his perspective on #hypercortisolism and highlights the challenges patients face on their diagnostic journeys. You can find more information on the book here: https://lnkd.in/gZbp2v3J #endocrinology
Cushing's: a comprehensive guide to understanding a devastating disease - Pituitary World News
https://pituitaryworldnews.org
-
#Hypercortisolism in adults with difficult-to-control type 2 #diabetes might be more prevalent than previously thought. Check out this article in Healio by Michael Monostra that includes data from our CATALYST trial: https://lnkd.in/gk_WqXA2 #ADA2024 #ADAScientificSessions #T2D
Hypercortisolism prevalent among 24% of adults with difficult-to-control type 2 diabetes
healio.com
-
#CushingsSyndrome, or #hypercortisolism, is often misunderstood and misdiagnosed. Stories like Ana’s are important to increase awareness and help patients get the right care. Thank you PITUITARY WORLD NEWS for sharing. #endocrinology
Ana’s story highlights adrenal diseases and the fact that some people with high cortisol levels are going to look like the classic patient with hypercortisolism, with symptoms and signs but not the textbook picture of Cushing’s. It was Ana’s work to push forward to get a diagnosis and understand what was going on with her, which led to a diagnosis that might have been otherwise considerably delayed. https://lnkd.in/g5C3MegS
Grand Rounds, Episode 3: Disorders of Cortisol Secretion Related to Adrenal Conditions
https://www.youtube.com/
-
Thank you HCPLive for hosting this discussion. #hypercortisolism #type2diabetes
🚨 New #DiabetesDialogue! 🚨 Hear from John Buse, MD, PhD, as he discusses why he says the 2-part CATALYST trial might be the "biggest thing that I have ever done in my career" with Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES and Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES. Get a deep dive into the trial, including part 2, which will examine use of mifepristone (Korlym; Corcept Therapeutics) among patients who screened positive for hypercortisolism. https://lnkd.in/et4uQuDg #Type2Diabetes #Hypercortisolism
-
Our Patient Advocate, Jessica Behrend, RN, MSN, FNP-BC, shares more about her experience working with people with #Cushing’s Syndrome here: https://bit.ly/4cGYBHt #CushingsSyndrome #endocrinology #hypercortisolism
-
-
Our CATALYST trial examined the prevalence of #hypercortisolism among people with difficult-to-control type 2 #diabetes. Learn more in this article from Patrick Campbell at HCPLive: https://lnkd.in/gmFDQYF8 #ADA2024 #ADAScientificSessions #T2D
CATALYST Proves Hypercortisolism More Common than Previously Known in Type 2 Diabetes
hcplive.com